Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Orion

63.3

 

EUR

 

-1.09 %

13,993 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Investor consensus

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
8.93B EUR
Turnover
12.4M EUR
P/E (adj.) (25e)
27.13
EV/EBIT (adj.) (25e)
21.29
P/B (25e)
8.07
EV/S (25e)
5.51
Dividend yield-% (25e)
2.69 %
Coverage
Recommendation
Reduce
Target price
50.00 EUR
Updated
2025-04-24
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18/7
2025

Interim report Q2'25

15/10
2025

Half year dividend

28/10
2025

Interim report Q3'25

Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Press release6/3/2025, 8:30 PM

U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer

Orion
Press release5/23/2025, 9:40 AM

Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market

Orion
Orion Capital Markets Day 2025
Webcast5/22/2025, 10:00 AM

Orion Capital Markets Day 2025

Orion

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/22/2025, 7:15 AM

Orion to host Capital Markets Day today, 22 May 2025, in Helsinki

Orion
Press release5/21/2025, 4:30 AM

Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers

Orion
Analyst Comment5/13/2025, 9:57 AM by
Antti Siltanen

Trump vs. Big Pharma – Round One

The US presidential administration has initiated measures to lower drug prices. With Monday's executive order, the administration aims to lower drug prices to the level of other developed countries.

OrionHerantis PharmaFaron PharmaceuticalsModulight
Regulatory press release5/8/2025, 1:30 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release5/7/2025, 2:00 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release5/6/2025, 3:00 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release5/5/2025, 2:00 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release5/2/2025, 12:15 PM

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion
Regulatory press release5/2/2025, 8:45 AM

Orion Corporation: Managers’ transactions – Henrik Stenqvist

Orion
Regulatory press release5/2/2025, 8:45 AM

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

Orion
Regulatory press release5/2/2025, 8:45 AM

Orion Corporation: Managers’ transactions – Hilpi Rautelin

Orion
Regulatory press release5/2/2025, 8:45 AM

Orion Corporation: Managers’ transactions – Maziar Mike Doustdar

Orion
Regulatory press release5/2/2025, 8:45 AM

Orion Corporation: Managers’ transactions – Eija Ronkainen

Orion
Regulatory press release5/2/2025, 8:45 AM

Orion Corporation: Managers’ transactions – Ari Lehtoranta

Orion
Regulatory press release5/2/2025, 8:45 AM

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

Orion
Regulatory press release5/2/2025, 8:45 AM

Orion Corporation: Managers’ transactions – Kari Jussi Aho

Orion
Regulatory press release5/2/2025, 6:00 AM

301,521 Orion Corporation A shares converted into B shares

Orion
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.